S10. Biologics and small molecules in 2020
Room 1, December 17 (Thu) , 09:00-10:30
more
09:00-09:20 |
Anti-TNFs: Old school or still gold standard? Makoto Naganuma, Kansai Medical University, Japan |
|
09:20-09:40 |
Emerging biologics: What will be a new hero? Edward V. Loftus, Jr., Mayo Clinic, USA |
|
09:40-10:00 |
Small molecules: Which are the most promising? Laurent Peyrin-Biroulet, Nancy University Hospital, France |
|
10:00-10:15 |
Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn's disease: A retrospective multi-centre study Michael De Gregorio, St Vincent's Hospital Melbourne, Australia |
|
10:15-10:30 |
Real-world effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study) Wei-Chen Lin, Mackay Memorial Hospital, Taiwan |
SS06. Multilayered remission in IBD, is it time to be more ambitious?
Room 2, December 17 (Thu) , 09:30-10:30
more
09:30-10:00 |
Why target multilayered remission in IBD? Takanori Kanai, Keio University, Japan |
|
10:00-10:30 |
What does it look like in IBD? Byong Duk Ye, University of Ulsan, Korea |
S11. Challenges in special situations: Experts share hot tips
Room 3, December 17 (Thu) , 09:00-10:30
more
09:00-09:20 |
Ulcerative colitis in the elderly: Essentials for clinical care Masaaki Higashiyama, National Defense Medical College, Japan |
|
09:20-09:40 |
Clinical care pathway for pregnancy in IBD Rupert Leong, University of Sydney, Australia |
|
09:40-10:00 |
Management of IBD in COVID-19 pandemic era Yan Chen, Zhejiang University, China |
|
10:00-10:15 |
Risk of vertebral and hip fracture in patients with inflammatory bowel diseases: A nationwide population-based study Hyung Jin Ahn, Asan Medical Center, Korea |
|
10:15-10:30 |
Impact of the COVID-19 pandemic on disease and psychological outcomes: A multi-national longitudinal study in inflammatory bowel disease Ines A Trindade, CINEICC, University of Coimbra, Portugal |
S12. Endoscopy in IBD: Seeing more and intervening better
Room 1, December 17 (Thu) , 10:50-12:20
more
10:50-11:10 |
Recent progress in the endoscopic scoring system Vineet Ahuja, All India Institute of Medical Sciences, India |
|
11:10-11:30 |
Appropriate use of small bowel endoscopy Jinsu Kim, The Catholic University of Korea, Korea |
|
11:30-11:50 |
The present and future of endoscopic intervention Kenji Watanabe, Hyogo College of Medicine, Japan |
|
11:50-12:05 |
Disease activity monitoring and therapeutic optimization using conventional and magnifying endoscopy in patients with ulcerative colitis in clinical remission Katsuyoshi Ando, Asahikawa Medical University, Japan |
|
12:05-12:20 |
When less is more and more is less; the inter-rater reliability of the endoscopic findings of pouchitis Zaid S Ardalan, Alfred Health and Monash University, Australia |
S13. Optimal therapeutic strategies: Thinking out of the box
Room 2, December 17 (Thu) , 10:50-12:20
more
10:50-11:10 |
Choosing the right therapy after conventional treatment failure Chang Hwan Choi, Chung-Ang University, Korea |
|
11:10-11:30 |
Controversies and solutions in non-responders to anti-TNF Mark Silverberg, Mount Sinai Hospital, Canada |
|
11:30-11:50 |
De-escalation of therapy in patients with quiescent IBD Taku Kobayashi, Kitasato University Kitasato Institute Hospital, Japan |
|
11:50-12:05 |
Vedolizumab is superior to anti-tumour necrosis factor agents as a first-line biological agent but not as a second-line biological agent in moderate to severe ulcerative colitis Aviv Pudipeddi, Concord Repatriation General Hospital, Australia |
|
12:05-12:20 |
Upfront surgery versus initial anti-TNF therapy for structural bowel damage in Crohns disease Wenwei Qian, Jinling Hospital, China |
S14. Asian guideline for IBD management
Room 3, December 17 (Thu) , 10:50-12:20
more
10:50-11:10 |
International guidelines in Asia: Are they feasible and necessary? Katsuyoshi Matsuoka, Toho University Sakura Medical Center, Japan |
|
11:10-11:30 |
Lessons from ECCO for developing international guidelines Joana Torres, Hospital Beatriz Ângelo, Portugal |
|
11:30-11:50 |
How to develop Asian guidelines for IBD? Dong Il Park, Sungkyunkwan University, Korea |
|
11:50-12:20 |
Discussion |
SS07. Raising the bar in ulcerative colitis treatment
Room 1, December 17 (Thu) , 12:20-13:20
more
12:20-12:45 |
Adopting histological healing as next therapeutic target: are we ready? Young-Ho Kim, Sungkyunkwan University, Korea |
|
12:45-13:20 |
Clinical evidence of ustekinumab in ulcerative colitis Miguel Regueiro, Cleveland Clinic, USA |
SS08. Optimizing outcomes through targeting gut and systemic inflammation in ulcerative colitis
Room 2, December 17 (Thu) , 12:20-13:20
more
12:20-12:50 |
Tight monitoring & inflammation control in ulcerative colitis Jae Hee Cheon, Yonsei University, Korea |
|
12:50-13:20 |
Optimizing outcome through targeting systemic inflammation in ulcerative colitis with anti-TNF Tae Oh Kim, Inje University, Korea |
SS09. JAK inhibition in UC: Focus on tofacitinib
Room 3, December 17 (Thu) , 12:20-13:20
more
12:20-12:50 |
Tofacitinib in UC: Exploring the efficacy and safety profile Laurent Peyrin-Biroulet, Nancy University Hospital, France |
|
12:50-13:20 |
Practicalities of Tofacitinib in UC: Dosing and monitoring in appropriate patients Bora Keum, Korea University, Korea |
PL. AOCC Plenary Session (Part 1)
Room 1, December 17 (Thu) , 13:40-14:25
more
13:40-13:55 |
Multiscale 3D imaging of whole gut enteric nervous system in mouse and human using tissue clearing and its applications in IBD patients Young Hyun Yun, Seoul National University, Korea |
|
13:55-14:10 |
Hsa_circRNA_102610 promotes growth and TGF-β1 induced EMT of intestinal epithelial cells by sponging hsa_miR-130a-3p Zhi Pang, Suzhou Municipal Hospital, China |
|
14:10-14:25 |
Personalised nanomedicine: Precision nanotherapy based in-vitro and in-vivo paradigm for reducing severity of inflammation in acute experimental ulcerative colitis Anas Ahmad, Institute of Nano Science and Technology (INST), India |
PL. AOCC Plenary Session (Part 2)
Room 1, December 17 (Thu) , 14:25-15:10
14:25-14:40 |
Host genetic and gut microbial signatures in familial inflammatory bowel disease Ga Young Shin, Kyung Hee University Medical Center, Korea |
|
14:40-14:55 |
Efficacy and safety of Filgotinib as induction therapy for patients with moderately to severely active ulcerative colitis: Results from the phase 2b/3 SELECTION study Hyo Jong Kim, Kyung Hee University Hospital, Korea |
|
14:55-15:10 |
Pathway of focal adhesion and its relevant circRNAs and lncRNAs are involved with perianal Crohn's disease Shi-Xue Dai, Guangdong Provincial People's Hospital, China |
S15. Current IBD care in Asia: Real-life situation
Room 2, December 17 (Thu) , 13:40-15:10
more
13:40-14:00 |
Diagnosis of IBD - Asian perspectives Han Hee Lee, The Catholic University of Korea, Korea |
|
14:00-14:20 |
Treatment of IBD Eun Mi Song, Ewha Womans University, Korea |
|
14:20-14:40 |
Infections in IBD Seong-Joon Koh, Seoul National University, Korea |
|
14:40-15:00 |
Vaccination in IBD Subum Park, Pusan National University, Korea |
|
15:00-15:10 |
Discussion |
S16. Tailored care for pediatric IBD: Children growing up
Room 3, December 17 (Thu) , 13:40-15:10
more
13:40-14:00 |
Infantile and very-early-onset IBD Jin Soo Moon, Seoul National University, Korea |
|
14:00-14:20 |
Transition care of adolescents with IBD Marion Aw, National University of Singapore, Singapore |
|
14:20-14:40 |
Personalized treatment in pediatric IBD Katsuhiro Arai, National Center for Child Health and Development, Japan |
|
14:40-14:55 |
Clinical implication of VEOIBD (Very Early Onset Inflammatory Bowel Disease) gene panel on patients with intestinal inflammation Min Soo Kim, Seoul National University Hospital, Korea |
|
14:55-15:10 |
Identification of immune landscapes and molecular subtypes in pediatric Crohn's disease Shiyu Xiao, Peking University Third Hospital, China |
S17. Toward a systemic approach with precision medicine
Room 1, December 17 (Thu) , 15:30-17:00
more
15:30-15:50 |
How can we integrate multiomics and clinical data to predict disease course? Dermot P.B. McGovern, Cedars-Sinai Medical Center, USA |
|
15:50-16:10 |
How can we predict drug responses in the era of biologics? Chang Soo Eun, Hanyang University, Korea |
|
16:10-16:30 |
How can we use microbiome data for precision medicine? Harry Sokol, Saint-Antoine Hospital, France |
|
16:30-16:45 |
DNA methylation profiles accurately predict response to vedolizumab and remain stable during induction and maintenance treatment in Crohns disease Vincent Wilhelmus Joustra, Amsterdam UMC location AMC, Netherlands |
|
16:45-17:00 |
A novel model for predicting the efficacy of infliximab in ulcerative colitis patients based on random forest and artificial neural network Jing Feng, Renji Hospital, China |
S18. KASID-GEST Joint Symposium
Room 2, December 17 (Thu) , 15:30-17:00
more
15:30-15:50 |
Evolving epidemiology of colitis-associated cancer Hyun Gun Kim, Soon Chun Hyang University, Korea |
|
15:50-16:10 |
Surveillance endoscopy for detection of dysplasia: Chromoendoscopy or other technologies? Tien-Yu Huang, Tri-Service General Hospital, Taiwan |
|
16:10-16:30 |
Endoscopic treatment of colitis-associated dysplasia/cancer Dong-Hoon Yang, University of Ulsan, Korea |
|
16:30-16:50 |
Chemoprevention of colitis-associated dysplasia/cancer in IBD Hsu-Heng Yen, Changhua Christian Hospital, Taiwan |
|
16:50-17:00 |
Discussion |
S19. Region-specific Forum
Room 3, December 17 (Thu) , 15:30-17:00
more
15:30-15:45 |
Common colonic disease in Mongolia Bayasgalan Luvsandagva, Mongolian National University of Medical Sciences, Mongolia |
|
15:45-16:00 |
Double balloon enteroscopy to diagnose small bowel diseases at Bach Mai Hospital, Hanoi, Vietnam Nguyen Hoai Nam, Bach Mai Hospital, Vietnam |
|
16:00-16:15 |
Inflammatory bowel disease registry in low incidence country: Indonesia experience Murdani Abdullah, Dr. Cipto Mangunkusumo, Indonesia |
|
16:15-16:30 |
Inflammatory bowel disease in Thailand in the last 2 decades - patterns of diagnosis, treatment, and outcomes Julajak Limsrivilai, Siriraj Hospital, Mahidol University, Thailand |
|
16:30-17:00 |
Discussion |